Table 1.
Baseline Characteristics of AML Patients received the Thai MDASI-AML/MDS assessment (n=20)
| Baseline characteristics | N = 20 |
|---|---|
| Female, n (%) | 11 (55) |
| Age, mean ± SD | 45.9 ± 18.9 years |
| < 40 years, n (%) | 9 (45) |
| 40-60 years, n (%) | 6 (30) |
| > 60 years, n (%) | 5 (25) |
| AML risk classification | |
| Favorable, n (%) | 2 (10) |
| Intermediate, n (%) | 12 (60) |
| Unfavorable, n (%) | 6 (30) |
| Treatment | |
| Induction: 7+3 regimen, n (%) | 8 (40) |
| Consolidation: Intermediate-dose Cytarabine, n (%) | 5 (25) |
| Hypomethylating agents: Azacytidine, n (%) | 7 (35) |
| Hospitalization, mean ± SD | 29.7 ± 22.3 days |
| ≤ 30 days, n (%) | 13 (65) |
| > 30 days, n (%) | 7 (35) |
| Duration between diagnosis to assessment, mean ± SD | 27.6 ± 19.9 days |
| Disease status | |
| Complete remission, n (%) | 8 (40) |
| Relapse or refractory, n (%) | 2 (10) |
| Pending for disease evaluation, n (%) | 10 (50) |